Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Craig Hallum

Craig Hallum began coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report report published on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $68.00 price target on the stock.

Several other equities analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Leerink Partners began coverage on shares of Quince Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 price target on the stock. Oppenheimer initiated coverage on shares of Quince Therapeutics in a research report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price target on the stock. Lifesci Capital raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $70.00 price objective on shares of Quince Therapeutics in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $260.00.

Quince Therapeutics Stock Performance

Quince Therapeutics stock opened at $33.93 on Thursday. The firm has a market capitalization of $34.61 million, a price-to-earnings ratio of -0.22 and a beta of 1.36. Quince Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $909.98. The stock’s fifty day moving average is $22.45 and its two-hundred day moving average is $24.99.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71.

Institutional Trading of Quince Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new position in Quince Therapeutics in the 2nd quarter valued at about $4,172,000. Adage Capital Partners GP L.L.C. purchased a new position in Quince Therapeutics in the 4th quarter valued at about $7,538,000. Millennium Management LLC boosted its stake in shares of Quince Therapeutics by 1,152.9% during the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after purchasing an additional 1,276,094 shares during the last quarter. Superstring Capital Management LP acquired a new stake in shares of Quince Therapeutics during the 4th quarter worth about $2,877,000. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Quince Therapeutics by 442.1% during the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock worth $1,263,000 after buying an additional 632,076 shares in the last quarter. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.